Quantifying Medical Value via Incremental Cost-Effectiveness Analysis

This direction is merged into another direction: incremental cost-effectiveness ratio, probabilistic sensitivity analysis. Its last version stays readable and citable here.

Version 1 of 131 papers36 conceptsfrozen 2026-10-04

In modern medicine, the primary hurdle for a new intervention is no longer just "Does it work?" but "Is it worth it?" As high-tech robotic surgeries, immunotherapies, and AI diagnostics enter the market, healthcare systems must decide which "songs" are worth the premium and which are simply expensive noise. Anobel Odisho and colleagues famously framed this as the Singer vs. the Song debate: does the technology (the song) provide the value, or is it the skill of the practitioner (the singer)?

To answer this, researchers use a rigorous framework called Incremental Cost-Effectiveness Analysis (ICEA). This approach moves beyond simple price tags to calculate the marginal cost of every extra unit of health gained.

The Core Metric: The ICER

The fundamental tool of this field is the Incremental Cost-Effectiveness Ratio (ICER). It is a simple fraction that reveals the trade-off of switching from a standard treatment to a new one:

$$\text{ICER} = \frac{\text{Cost}_{\text{new}} - \text{Cost}_{\text{old}}}{\text{Effect}_{\text{new}} - \text{Effect}_{\text{old}}}$$

As Yalin Dong demonstrates in the context of antibiotic-induced kidney injury, the ICER allows us to see if the extra cost of a safer drug combination is justified by the number of complications it prevents.

However, "effects" can be measured in many ways—cases of cancer detected, infections avoided, or years of life saved. To compare a heart valve procedure in Singapore (Ivandito Kuntjoro) against a depression screening in China (Yehuan Yang), we need a universal currency of health.

Standardizing Benefit with QALYs

The Quality-Adjusted Life Year (QALY) is that currency. It weights a year of life by the quality of that life (where 1.0 is perfect health and 0.0 is death).

By using QALYs, researchers like Léon Nshimyumukiza can compare blood thinners not just by how many strokes they prevent, but by how much "total healthy life" they add to a population. This "cost-utility" approach is essential for evaluating expensive immunotherapies. For instance, Zhuo‐miao Ye found that while certain cancer drug combinations significantly extend life, their cost per QALY exceeds $372,000—far beyond what most societies are willing to pay.

The Threshold of Willingness to Pay

An ICER is only meaningful when compared to a Willingness-to-Pay (WTP) threshold. This threshold is often tied to a country's economic strength (e.g., 1–3 times the per-capita GDP).

  • Cost-Effective: If the ICER is below the threshold, the intervention is considered a good value. Shujing Zhang showed that adjuvant pembrolizumab for melanoma falls well within these bounds in the U.S.
  • Economically Dominated: If a new treatment is both more expensive and less effective (or equally effective) than the old one, it is "dominated." Sai Zhang notes that Hepatitis C treatments can be dominated if their price-to-performance ratio is inferior to existing cures.
  • Dominant: The "holy grail" of healthcare. A dominant strategy is one that is both more effective and cheaper than the alternative. Maobai Liu identified azithromycin for C-sections as a dominant strategy, as it prevents enough infections to pay for itself.

Modeling Uncertainty and Sensitivity

Because clinical trials only last a few years, researchers use Markov models to simulate the long-term economic impact over a patient's lifetime. Shuyi Ding used these models to project the value of CAR-T cell therapy in China, accounting for potential relapses years down the line.

To ensure these models are robust, sensitivity analysis is used to find the "tipping point." Francis K.L. Chan used this to determine exactly how much a protective pill must cost before a more expensive arthritis drug becomes the more economical choice.

Expanding the Scope: AI and Information

The framework is now expanding beyond drugs and surgery. Beini Fei is applying ICERs to AI-driven gait screening, asking if the cost of the software is justified by the extra cases of cerebrovascular disease it catches.

Perhaps most radically, Shuhan He suggests we should measure the entropy removal of a diagnostic test. In this view, the "value" of a medical test is the amount of clinical uncertainty it eliminates per dollar spent. Whether through information theory or QALYs, the goal remains the same: ensuring that every dollar spent on the "song" results in the best possible performance for the patient.

Papers in this version

History & citationVersion 1 · 2026-10-04

Merged into another direction · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_quantifying_medical_value_via_incrementa_edfdd4ce,
  title = {Quantifying Medical Value via Incremental Cost-Effectiveness Analysis},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/quantifying-medical-value-via-incremental-cost-effectiveness-analysis/rdr_edfdd4ce6dfd412d806552c5e8a158ef},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_quantifying_medical_value_via_incrementa_edfdd4ce_v1,
  title = {Quantifying Medical Value via Incremental Cost-Effectiveness Analysis},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/quantifying-medical-value-via-incremental-cost-effectiveness-analysis/rdr_edfdd4ce6dfd412d806552c5e8a158ef/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}